Crossref
26-A-12564-ACC EFFECTIVENESS OF LDL-C LOWERING WITH ALIROCUMAB AND INCLISIRAN IN A CLINICAL PRACTICE SETTING
JACC · 2026-04 · 87 (13) · A271
DOI: 10.1016/j.jacc.2026.02.673 ↗Kurz gefasst
Fachartikel in der Zeitschrift JACC, 2026-04. Verfasst von Maciej Banach und 9 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Banach, M., carro, A., Schulte, D., Halvorsen, S., Khan, I., Tavori, H., lou, Z., Hegele, R., Achirica, M. C., & Leósdóttir, M. (2026). 26-A-12564-ACC EFFECTIVENESS OF LDL-C LOWERING WITH ALIROCUMAB AND INCLISIRAN IN A CLINICAL PRACTICE SETTING. JACC, 87(13), A271. https://doi.org/10.1016/j.jacc.2026.02.673
Vancouver
Banach M, carro A, Schulte D, Halvorsen S, Khan I, Tavori H, et al. 26-A-12564-ACC EFFECTIVENESS OF LDL-C LOWERING WITH ALIROCUMAB AND INCLISIRAN IN A CLINICAL PRACTICE SETTING. JACC. 2026;87(13):A271. doi:10.1016/j.jacc.2026.02.673
BibTeX
@article{Banach2026,
author = {Banach, Maciej and carro, amelia and Schulte, Dominik and Halvorsen, Sigrun and Khan, Irfan and Tavori, Hagai and lou, zhouyang and Hegele, Robert and Achirica, Miguel Cainzos and Leósdóttir, Margrét},
title = {26-A-12564-ACC EFFECTIVENESS OF LDL-C LOWERING WITH ALIROCUMAB AND INCLISIRAN IN A CLINICAL PRACTICE SETTING},
journal = {JACC},
year = {2026},
volume = {87},
number = {13},
pages = {A271},
doi = {10.1016/j.jacc.2026.02.673}
}
EUVIMED